GILD Gilead Sciences
- 86.750
- +0.930+1.08%
- 86.370
- -0.380-0.44%
Gilead Sciences News
Gilead Sciences | 8-K: Gilead Sciences Reports Second Quarter 2024 Financial Results
Gilead Sciences | 8-K: Gilead Sciences Announces Dr Merdad V. Parsey is Leaving the Company
Gilead Sciences | 8-K: Poll Results of 2024 Annual Meeting of Shareholders
Gilead Sciences | 8-K: Gilead Sciences Announces First Quarter 2024 Financial Results
Gilead Sciences | DEF 14A: Definitive information statements
Gilead Sciences | DEFA14A: Others
Gilead Sciences | 8-K: Gilead Sciences Announces Completion of Acquisition of CymaBay Therapeutics and Enters into an Agreement and Plan of Merger with Wholly-Owned Subsidiary Pacific Merger Sub
Gilead Sciences | PRE 14A: Preliminary proxy statements relating to merger or acquisition
Gilead Sciences | 8-K: Kevin E. Lofton Will Retire from the Board
Gilead Sciences | 8-K: Agreement and Plan of Merger
Gilead Sciences | 8-K: Gilead Sciences Reports Fourth Quarter and Full Year 2023 Financial Results
Gilead Sciences | 8-K: Gilead Sciences Appoints Dr. Ted W. Love to Board of Directors
Gilead Sciences | 8-K: Gilead Sciences Announces Third Quarter 2023 Financial Results
Gilead Sciences | 8-K: Entry into Underwriting Agreements
Gilead Sciences | 8-K: Presentation of Sacituzumab Govitecan + Pembrolizumab in 1L Metastatic Non-Small Cell Lung Cancer: Preliminary Results of the EVOKE-02 Study in WCLC
Gilead Sciences | S-8: Initial registration statement for securities to be offered to employees pursuant to employee benefit plans
Gilead Sciences | S-3ASR: Automatic shelf registration statement of securities of well-known seasoned issuers
Gilead Sciences | 8-K: Gilead Sciences Reports Second Quarter 2023 Financial Results
Gilead Sciences | 8-K: Amendment and Restatement Employee Stock Purchase Plan and Voting Results 2023 Annual Meeting of Stockholders
Gilead Sciences | 8-K: GILEAD SCIENCES ANNOUNCES FIRST QUARTER 2023 FINANCIAL RESULTS
Analysis
Price Target
No Data
No Data
